The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I'm with you Dhub. Interims may well have some good content to continue the upward trend. If only focusing on CAR-T, then lifting of CH would be momentous for the company and a pathway to going clinical. I get plenty of reassurance from the latest round of funding as they will have undertaken plenty of DD, plus FDA has agreed the 'fix', so I assume DVS knows how to fix it and should then fly through approval.
Who knows on CBR... the mysterious panacea. Any favourable update on CBR will spike the SP too. 6p may be underestimating things by Christmas!
Really positive. My takeaway is... the investor will have done DD and had extensive discussions with DVS on how to lift CH. FDA has agreed the plan, DVS must have the solution. That means we are going clinical IMO. Brill.
Like buses, the RNS keep on coming.
Just thought I would drop in to say Hi. Still in a holding pattern. Timings are all conjecture but late Sep/ early Oct feels about right assuming no export challenges. I assume SP will lock into the 1.5 - 1.6 range until news (positive or negative) on CAR-T. Here's hoping for a CBR update too. CDX I've discounted completely for now.
I'm with you Micky. I would have expected some form of correspondence from the FDA (albeit I think they have 30 days to issue their explanation), and then the company updating us as to the nature of the issue and (hopefully) that its an easy fix. HEMO really is an information desert.
Can't argue with 50% in a week, lets be honest, and if I was a trader, that would be a good week! That said... I'm with Bline and holding for an extra zero on that %. HEMO is the most annoying share I have, literally £50k swings in a week, up and down. Let's hope Vlad knows how to fix the IND Hold. SP should double on that. Then into trials... (nervous face).
DVS posted this on youtube too https://www.youtube.com/watch?v=4u9NRLi67oE&feature=youtu.be
Agreed Dhub, nice to see a rise. Great opportunity for newbies to get in cheap. Would be even better to hear from the company on a revised FDA submission or CBR update. As with many of the LTH, I'm just sitting and waiting... have been patient for 4 years. Can wait a bit longer!
Not a lot has changed in my opinion. If FDA wants clarification/further information/testing. OK, we will undertake that and resubmit as required. Time and cost. Yes, end of CAR-T, No. Obviously frustrating but it could never have been the intention of HEMO to submit something that was going to be put on hold (not rejected).
I've been here long enough that the bottom drawer has plenty of space for HEMO shares. Fast forward 3 months and see where we are then. The logic of the science still holds, and assuming it is clarification/information that the FDA wants (hopefully more detail on this from DVS interview) which can be addressed, then only a timing issue.
I could sell for a small loss, but very much still a hold for me.
We have got to be so close now. The early FDA dialogue, the delayed submission to ensure that documentation was right, three successful PQs, third party verification of the PQs. Surely, this preparation will mean we will go clinical.
2.14p to buy on HL. Let the tick up commence... I know it is conjecture but with IND and commencing clinical trials we deserve an uplift on SP. Approach the 4p that was seen earlier in the year?
Wow - not seen 6m for a sell before... probably because I only have 3.3m. Must be positive them wanting to hoover up shares though. Tick tock, but by heck, it's a boring wait. Enjoy the sunshine weekend. Maybe next week Rodney.
All very slow atm, I'm surprised there hasn't been any uptick as the days pass by, even from speculative investors. So what is the desired outcome:
1. IND being received or rather not being declined.
2. HEMO in the background identifying and agreeing to work with a partner
3. Patients ready to go. Sadly AML kills quickly with no real cure and so hopefully there will be many interested in experimental trials given any potential side effects are unlikely to outweigh the potential upside of an experimental trial.
I would like to see all three above in the same RNS or shortly after each other.
Nice little upward tick on no volume. i would expect interest to start improving on a daily basis as we approach a decision day. Surely we will be above recent highs by the time IND arrives.
Also... CBR in the background is due a bit of news. Cheeky RNS confirming that it has worked in vivo on a range of diseases would be massive news. Panacea time!